New drug CTX-10726 tested for advanced cancers: hope for patients out of options

NCT ID NCT07419841

First seen Mar 18, 2026 · Last updated May 16, 2026 · Updated 9 times

Summary

This early-phase study tests a new drug called CTX-10726 in people with advanced cancers (stomach, liver, uterine, or kidney) that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 70 adults will take part, and the study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Prisma Health Cancer Institute

    NOT_YET_RECRUITING

    Greenville, South Carolina, 29605, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • START New York

    RECRUITING

    Lake Success, New York, 11042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.